This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A New Way To Stay Well: Alomune Launches In The US

NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Lonza, a global leader in the life sciences industry, is pleased to announce the launch of Alomune, a safe, daily immune supplement made with natural extracts from the renewable Minnesota Larch Tree that optimize the body's immune response to help people stay healthy.

"We are extremely pleased to introduce Alomune to the market," said Marshall Fong, Director of Consumer Marketing for Lonza. "Unlike many other immune products currently available to consumers, Alomune is meant to be taken daily, when you do feel well. Consumers tell us that they are extremely interested in trying products like Alomune and would prefer them over the types of immune products you often find in stores today that are designed to be taken when you don't feel well."

The main ingredient in Alomune, larch arabinogalactan, is an immune-enhancing, plant-based carbohydrate that is extracted from larch trees, also known as Tamarack. Larch arabinogalactan counts toward daily fiber intake and has antioxidant activity, as measured by Oxygen Radical Absorbance Capacity (ORAC) per 100 grams, similar to that of pomegranates. It is taken from densely populated larch trees in Minnesota under good state forestry management practices.

"Alomune is a vital addition to the wellness market that highlights the idea of maintaining the immune system to achieve good health," said Dr. Dan Johnston, military public health expert and Alomune spokesperson. "It's important to be as resilient as possible to immune challenges, and Alomune helps optimize the body's natural defenses, keeping it strong and protected."

One of the very few dietary supplements backed by the Good Housekeeping Seal, Alomune was tested in a 12-week, double-blind, placebo-controlled clinical trial on over 200 healthy adults that suggested that those who took Alomune daily had twice the odds of staying healthy on measured health outcomes versus those taking placebo. Among participants, 57% more stayed healthy taking Alomune versus the placebo.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs